<DOC>
	<DOCNO>NCT02726750</DOCNO>
	<brief_summary>The goal clinical research study find marker might help predict patient monoclonal gammopathy unknown significance ( MGUS ) smolder multiple myeloma ( SMM ) develop multiple myeloma , others . Markers study may include participant 's age , level protein blood urine , percent abnormal blood cell bone marrow , gene abnormal blood cell , bone abnormality .</brief_summary>
	<brief_title>Prospective Observational Study Clinical Genomic Predictors Progression Myeloma Asymptomatic Monoclonal Gammopathies</brief_title>
	<detailed_description>Study Visits : If participant find eligible take part study , every 6 month 3 year : - Participant physical exam . - Blood ( 1-2 tablespoon ) collect biomarker routine test check status disease . - A 24 hour urine sample collect routine test . - If doctor think need , participant bone marrow biopsy aspiration , PET/CT scan , and/or MRI . This may do , example , participant feeling well concern disease might develop multiple myeloma . One ( 1 ) time year 3 year , participant x-rays check status disease doctor think need . Length Study : Participant take study decide receive chemotherapy treatment disease first 3 year unable follow direction . Participant enter follow-up period early disease get bad . End-of-Study Visit : After 3 year study , follow test procedure perform : - Blood ( 1-2 tablespoon ) collect routine test , biomarker test , check status disease . - A 24 hour urine sample collect routine test . - Participant bone marrow biopsy aspiration check status disease biomarker test . - Participant x-rays check status disease . - If doctor think need , participant PET/CT scan and/or MRI . Long-Term Follow-Up : At least 1 time every 6 12 month 3 year study : - Blood ( 1-2 tablespoon ) collect routine test check status disease . - A 24 hour urine sample collect routine test . - If doctor think need , participant PET/CT scan , MRI , x-rays , and/or bone marrow biopsy aspiration . If disease get bad 3-year study period : - At least 1 time every 6 12 month , study staff call ask participant ask question regular clinic visit . These call last 15-20 minute . - Blood ( 2 teaspoon ) draw biomarker test . - Participant bone marrow aspiration biomarker test . This investigational study . Up 200 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Paraproteinemias</mesh_term>
	<mesh_term>Monoclonal Gammopathy Undetermined Significance</mesh_term>
	<criteria>1 . Patients monoclonal gammopathy unknown significance age ≥ 18 year old . Both criterion must meet : Serum monoclonal protein &lt; 3 g/dL urinary monoclonal protein &lt; 500 mg per 24 hour clonal bone marrow plasma cell &lt; 10 % Absence myeloma define event amyloidosis 2 . Patients smolder multiple myeloma age ≥ 18 year old . Both criterion must meet : Serum monoclonal protein ≥ 3 g/dL urinary monoclonal protein ≥ 500 mg per 24 hour and/or clonal bone marrow plasma cell 1060 % Absence myeloma define event amyloidosis 1 . Evidence myeloma define event biomarkers malignancy due underlie plasma cell proliferative disorder meeting least one following : Hypercalcemia : serum calcium &gt; 0.25 mmol/L ( &gt; 1 mg/dL ) high upper limit normal &gt; 2.75 mmol/L ( &gt; 11 mg/dL ) Renal Insufficiency : creatinine clearance &lt; 40 ml/min serum creatinine &gt; 2 mg/dL Anemia : hemoglobin value &lt; 10 g/dL 2 g/dL &lt; normal reference Bone lesion : one osteolytic lesion skeletal radiography , computerize tomography ( CT ) 2deoxy2 [ F18 ] fluoroDglucose positron emission tomography CT ( PETCT ) . Clonal bone marrow plasma cell percentage ≥ 60 % Involved : uninvolved serum free light chain ratio ≥100 measure Freelite assay ( The Binding Site Group , Birmingham , UK ) &gt; 1 focal lesion MRI study ( focal lesion must 5 mm size ) 2 . Prior concurrent systemic treatment asymptomatic monoclonal gammopathy Bisphosphonates permit Radiotherapy permit Prior treatment chemotherapy investigational agent asymptomatic gammopathy permit 3 . Plasma cell leukemia 4 . Uncontrolled intercurrent illness include limited active infection psychiatric illness/social situation would compromise compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Monoclonal gammopathy unknown significance</keyword>
	<keyword>MGUS</keyword>
	<keyword>Smoldering multiple myeloma</keyword>
	<keyword>SMM</keyword>
	<keyword>Asymptomatic monoclonal gammopathy</keyword>
	<keyword>Biomarker test</keyword>
	<keyword>Blood collection</keyword>
	<keyword>Blood draw</keyword>
</DOC>